What is Chordate Medical Holding AB Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Chordate Medical Holding AB's Sloan Ratio %
For the Medical Devices subindustry, Chordate Medical Holding AB's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chordate Medical Holding AB's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Chordate Medical Holding AB's Sloan Ratio % falls into.
Chordate Medical Holding AB Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Chordate Medical Holding AB's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was -9.843 (Dec. 2023 ) + -6.019 (Mar. 2024 ) + -7.023 (Jun. 2024 ) + -5.681 (Sep. 2024 ) = kr-28.57 Mil.
Chordate Medical Holding AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was -7.502 (Dec. 2023 ) + -5.908 (Mar. 2024 ) + -6.999 (Jun. 2024 ) + -6.841 (Sep. 2024 ) = kr-27.25 Mil.
Chordate Medical Holding AB's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was -0.488 (Dec. 2023 ) + -0.78 (Mar. 2024 ) + -1.863 (Jun. 2024 ) + -0.237 (Sep. 2024 ) = kr-3.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chordate Medical Holding AB (OSTO:CMH) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Sep. 2024, Chordate Medical Holding AB has a Sloan Ratio of 11.19%, indicating there is a warning stage of accrual build up.
Chordate Medical Holding AB Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Chordate Medical Holding AB's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:CMH has been successfully added to your 